Latest News

BioPioneers ’ Angel & Pre-Seed Playbook was a masterclass in what actually gets the first check in biotech/techbio: Top takeaways - Scientists often jump to mechanism — investors first need the problem, stakes, and market. - At pre-seed, it’s mostly team + narrative; the seed bar is rising fast (more proof expected). - In TechBio/AI: more data ≠ more value. Show a feedback loop, proprietary/credible biology, and a few sharp use cases. - Fundraising mechanics matter: party rou

Funding isn’t dead, it’s concentrated. We gathered founders, operators, and investors to get tactical about what works now. Top takeaways  • Capital concentration: a few are very well funded; many aren’t. Differentiate or die.  • Stage rotation: Seed → Neuro, Series A → Autoimmune, Series B → Metabolic; Oncology cooled.  • Platforms must ship assets: Seed aim for in vivo; Series A leads with a standout asset + scalable platform.  • Operate in wartime: ruthless focus, cash dis